Akebia Therapeutics, Inc.AKBANASDAQ
Loading
Year-over-year free cash flow growth rate
Percentile
P49
Within normal range
vs 2Y Ago
0.2x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 10.49% |
| Q3 2025 | 26.14% |
| Q2 2025 | 263.31% |
| Q1 2025 | -204.50% |
| Q4 2024 | 33.28% |
| Q3 2024 | 33.66% |
| Q2 2024 | 48.05% |
| Q1 2024 | -741.94% |
| Q4 2023 | 67.80% |
| Q3 2023 | -297.49% |
| Q2 2023 | 120.69% |
| Q1 2023 | 67.93% |
| Q4 2022 | -261.75% |
| Q3 2022 | 210.26% |
| Q2 2022 | -41.07% |
| Q1 2022 | 65.40% |
| Q4 2021 | -11.62% |
| Q3 2021 | 10.88% |
| Q2 2021 | 10.82% |
| Q1 2021 | -127.68% |
| Q4 2020 | -13.99% |
| Q3 2020 | -173.39% |
| Q2 2020 | 141.50% |
| Q1 2020 | 2.99% |
| Q4 2019 | -1191.67% |
| Q3 2019 | 120.97% |
| Q2 2019 | 71.15% |
| Q1 2019 | -87.65% |
| Q4 2018 | -483.72% |
| Q3 2018 | -244.71% |
| Q2 2018 | 142.78% |
| Q1 2018 | -22.57% |
| Q4 2017 | 69.52% |
| Q3 2017 | -328.01% |
| Q2 2017 | 343.25% |
| Q1 2017 | -110.41% |
| Q4 2016 | 424.15% |
| Q3 2016 | -4.59% |
| Q2 2016 | -262.79% |
| Q1 2016 | 175.38% |